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Abstract
Human mesenchymal stem cell (hMSC)-based therapies are of increasing interest in the field of regenerative medicine. As
economic considerations have shown, allogeneic therapy seems to be the most cost-effective method. Standardized procedures
based on instrumented single-use bioreactors have been shown to provide billion of cells with consistent product quality and to be
superior to traditional expansions in planar cultivation systems. Furthermore, under consideration of the complex nature and
requirements of allogeneic hMSC-therapeutics, a new equipment for downstream processing (DSP) was successfully evaluated.
This mini-review summarizes both the current state of the hMSC production process and the challenges which have to be taken
into account when efficiently producing hMSCs for the clinical scale. Special emphasis is placed on the upstream processing
(USP) and DSP operations which cover expansion, harvesting, detachment, separation, washing and concentration steps, and the
regulatory demands.
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Introduction
There is an increasing interest in human mesenchymal stem
cell (hMSC)-based therapies for regenerative medicine (e.g.,
neurology, cardiology, immunology, orthopedics) (Aggarwal
and Pittenger 2005; Ohno et al. 2012). At the beginning of
November 2017, up to 190 clinical trials with hMSCs were
running, of which up to 80%were within phase I and II (www.
clinicaltrials.gov). These clinical trials are either done with the
patient’s own cells (autologous therapies) or with cells
provided by a healthy donor (allogeneic therapies) (Parton
and Mason 2012; Heathman et al. 2015). Despite the large
number of clinical studies, only 13 hMSC-based products
have gained marketing authorization up to the present day
(Heathman et al. 2015; Trounson and McDonald 2015;
Chen et al. 2016; Lodge et al. 2017). Table 1 shows the nine
products applicable for allogeneic therapies and the four prod-
ucts used for autologous transplantations. Product
manufacturing takes place mainly with mesenchymal stem
cells derived from human bone marrow (hBM-MSCs),
followed by adipose-derived stromal/stem cells (hASCs). In
addition, hMSCs derived from placental tissue, umbilical
cord, cord blood, and Wharton’s jelly have become more im-
portant over the last 5 years (Heathman et al. 2015; Nordberg
and Loboa 2015; Ullah et al. 2015; Chen et al. 2016).
To efficiently manufacture hMSC-based products, not only
must the targeted cell quantity and quality be taken into ac-
count but also the production costs. In Fig. 1a, b, the main
steps involved in producing hMSC-based therapeutics for al-
logeneic and autologous treatments are schematically
depicted. Both therapy approaches are characterized by simi-
lar manufacturing steps covering upstream processing (USP),
downstream processing (DSP), formulation, and Fill&Finish
operations. Typical USP operations are manufacture of the
Master Cell Bank (MCB) and Working Cell Bank (WCB),
seed cell production and subsequent cell expansion at
L-scale. DSP steps include cell harvest, detachment of the
hMSCs from their growth surface, cell separation, washing
as well as concentration procedures, and medium exchange.
However, before hMSCs can be administered as Advanced
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Therapeutic Medicinal Product (ATMP), additional formula-
tion and Fill&Finish steps must be carried out. The main dif-
ferences between allogeneic and autologous manufacturing
approaches are the number of therapeutic doses generated in
each batch during the cell expansion process as well as the
number of patients treated. The autologous approach gener-
ates multiple small batches, with each batch yielding one or a
few doses intended for one patient. In contrast, the allogeneic
approach providesmultiple doses for many patients. Doses are
manufactured in one large batch. Due to higher cost of goods
and the more crucial security and quality control described for
autologous manufacturing approaches, allogeneic stem cell
therapy seems to be the more commercially attractive option
at present (Malik and Durdy 2015). Different economic stud-
ies have demonstrated that the USP, and in particular, the
hMSC expansion, represents the main cost driver when exam-
ining the whole manufacturing process (Simaria et al. 2014;
Hassan et al. 2015; Lipsitz et al. 2017). In order to achieve the
high cell amounts of between 1012 and 1013 cells per batch in
allogeneic hMSC manufacturing process, the manufacturer
has to move away from the traditional planar cultivation plat-
forms. Typical cell concentrations (25,000–30,000 cells/cm2)
provided by common planar cultivation systems, which may
have up to 40 layers, cannot meet the desired cell numbers and
Fig. 1 Main operations required to manufacture hMSC-based therapeutics which are used in a allogeneic and b autologous therapies
Table 1 hMSC-based products with marketing authorization for allogeneic and autologous therapies
Medicinal product Company hMSC type Indication Marketing authorization
Allostem AlloSource Allogeneic hASC Bone regeneration US medical device
Cartistem Medipost Allogeneic UCB-MSC Osteoarthritis Korea
Grafix Osiris Therapeutics Allogeneic BM-MSC Soft tissue defects US medical device
Prochymal Mesoblast Allogeneic BM-MSC Graft-versus-host disease Canada and New Zealand
OsteoCel NuVasive Allogeneic BM-MSC Spinal bone regeneration US medical device
OvationOS Osiris Therapeutics Allogeneic BM-MSC Bone regeneration US medical device
TEMCELL HS JCR Pharmaceuticals Allogeneic BM-MSC Graft-versus-host disease Japan
Trinity Evolution Orthofix Allogeneic BM-MSC Bone regeneration US medical device
Trinity Elite Orthofix Allogeneic BM-MSC Bone regeneration US medical device
Hearticellgram-AMI Pharmicell Autologous BM-MSC Acute myocardial infarction Korea
Cupistem Anterogen Autologous hASC Crohn’s fistula Korea
QueenCell Anterogen Autologous hASC Regeneration of subcutaneous adipose tissue Korea
Ossron RMS Autologous BM-MSC Bone regeneration Korea
hASC human adipose tissue-derived stromal/stem cells, hBM-MSC human bone marrow-derived mesenchymal stem cells, UCB-MSC umbilical cord-
derived mesenchymal stem cells
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consistent quality, even at a high grade of automation and
parallelization (Rowley et al. 2012; Rios and Gupta 2016;
Abraham et al. 2017).
Instrumented, dynamic bioreactors operated with
microcarriers have shown promising results and are meanwhile
regarded as a viable alternative to planar cultivation systems in
hMSC expansions (Goh et al. 2013; Rafiq et al. 2013; Santos
2014; Chen et al. 2015). A further increase in USP process
safety during hMSC manufacturing was achieved by replacing
reusable bioreactors with their single-use versions (Schnitzler
et al. 2016; Lodge et al. 2017), which were originally designed
for mammalian cell-based productions of therapeutic proteins
(Kaiser et al. 2015). However, the production cells used here
are presumed to bemore robust and less sensitive to shear stress
than hMSCs (Schnitzler et al. 2016). In addition, the culture
media differ in their compositions, in particular, their supple-
ments and generally serum (up to 20%) are present in case of
hMSC expansions (Tekkatte et al. 2011; Panchalingam et al.
2015). These factors not only influence the selection of the
optimum microcarrier type but also those of the optimum
single-use bioreactor system and operation parameters (Tan
et al. 2015, 2016). Finally, the shear stress sensitivity of the
cells and the high target cell numbers and qualities affected
the equipment that is today recommended for the DSP in allo-
geneic hMSC productions.
Our mini-review will highlight the current state of the art of
allogeneic hMSC manufacturing and describe the main pro-
cess and regulatory challenges for USP and DSP operations.
Formulation techniques enabling the hMSCs to be frozen for
shipping and storage and easily thawing at the point of clinical
use will not be discussed.
USP in hMSC productions for allogeneic
therapies
Single-use bioreactors suitable for hMSC expansion
The majority of cultivation systems used to propagate and
expand hMSCs represent single-use versions. In other words,
the cultivation unit is only used once and discarded after run-
ning one batch. The single-use cultivation systems have a
rigid cylindrical cultivation vessel (made from polystyrene
or polycarbonate) or a flexible bag (with a polyethylene or
ethylene vinyl acetate contact layer). The bag is fixed and
shaped by a support container made from stainless steel and
is either similar to a pillow, cube-shaped or cylindrical (Eibl
et al. 2010; Eibl and Eibl 2011). Because the manufacturer
provides the cultivation chambers, presterilized, sterilization,
and cleaning procedures become obsolete. In addition, the risk
of cross contamination is reduced which makes the hMSC
expansion process safer (Kaiser et al. 2015). The disadvan-
tages are well described for static representatives of single-use
cultivation systems (planar multilayer flasks such as
CELLStack, HYPERStack, and CellFactories). So, their us-
age is associated with inefficient mass transfer, the presence of
nutrient gradients as well as inadequate process monitoring
and control. Regardless, planar multilayer flasks are currently
most often applied for the commercial manufacture of hMSCs
(Rowley et al. 2012). The fact that dynamic single-use culti-
vation systems operated with microcarriers ensure easier
scale-up explains the increasing interest in their usage for
hMSC expansions over the past 10 years. The cultivation sys-
tems cover non-instrumented stirred (spinner flasks) (Schop
et al. 2010; Kaiser et al. 2013; Jossen et al. 2016; Petry et al.
2016; Rafiq et al. 2017) as well as orbitally shaken flasks
(shake flasks or Erlenmeyers) (Siddiquee and Sha 2014a)
and instrumented single-use bioreactors, which are summa-
rized in Table 2. In the case of instrumented single-use biore-
actors, a distinction can be made between stirred bioreactors,
wave-mixed bioreactors, hollow fiber bioreactors, and fixed
bed bioreactors (Fig. 2).
Stirred bioreactor versions represent the system of choice
when expanding hMSCs in dynamic single-use bioreactors.
But as different investigations have already shown, the bio-
chemical engineering characterization prior to the usage of the
bioreactor system allows acceptable process parameters to be
predefined while avoiding cell damage and cell expansions
that have failed (Hewitt et al. 2011; Kaiser et al. 2013;
Schirmaier et al. 2014; Delafosse et al. 2015; Berry et al.
2016; Collignon et al. 2016; Jossen et al. 2016; Nienow
et al. 2016a, c). In fact, hMSC expansion was proposed to
be performed at impellers speeds, where the microcarriers
are just suspended (NJS = Ns1) or below (Ns1u) (Ibrahim and
Nienow 2004; Hewitt et al. 2011; Kaiser et al. 2013). Under
these conditions, a homogenous microcarrier distribution
resulting in a sufficient mass transfer is achievable at minimal
shear stress. Nevertheless, the acting shear stresses depend to a
large extent on the performance of the bioreactor. Single-use
stirred bioreactors equipped with segment blade impellers or
marine impellers induce an axial oriented fluid flow which is
beneficial for microcarrier-based hMSC expansions (Ibrahim
and Nienow 2004; Moayeri Kashani et al. 2016). As different
studies have shown, the performance of stirred single-use bio-
reactors for hMSC cultivations can be improved by adapting
the impeller diameter, impeller off-bottom clearance or impel-
ler blade angle (Collignon et al. 2010; Jirout and Rieger 2011;
Jossen et al. 2014).
Today, instrumented stirred single-use bioreactors are com-
mercially available at small, benchtop, and pilot/production
scale. As shown in Table 2, they are used up to 150 L working
volume and deliver maximum cell densities of 2 × 106 hMSC/
mL (Rios and Gupta 2016). Small-scale systems such as the
ambr® 15 and 250 as well as the BioBLU 0.3c are suitable for
medium-microcarrier screening or for scale down investiga-
tions (Szczypka et al. 2014; Dufey et al. 2016; Lipsitz et al.
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Table 2 Instrumented, dynamic single-use bioreactors operated with microcarriers. The order of the bioreactors within each category represents no
rating of the systems (alphabetically ordered)
Working
principle
Scale Manufacturer System brand Cell density/cell
type
References
Stirred systems Small-scale bioreactors
(15 mL–0.25 L)*
Sartorius Stedim
Biotech
ambr® 15/ambr® 250 4–5∙105 cells/mL
hBM-MSCs
Dufey et al. (2016); Nienow et al.
(2016b)
Eppendorf/
DASGIP
BioBLU® 0.3c
Benchtop scale bioreactors Eppendorf CelliGen® BLU 2.7–5.3∙105
cells/mL
hASCs,
hBM-MSCs
Milipore (2012); Cierpka et al. (2013);
Siddiquee and Sha (2014a, b, 2015);
Schirmaier et al. (2014); Jossen et al.
(2014); Grein et al. (2016)
(1.5–2.4 L)* Merck Mobius® CellReady
Sartorius Stedim
Biotech
UniVessel® SU
Pilot and production
scale bioreactors
Pall Life Sciences Allegro™ STR 1.9–20∙105
cells/mL
hASCs,
hBM-MSCs
Schirmaier et al. (2014); Rios and
Gupta (2016); Lawson et al. (2017)
(35–150 L)* Sartorius Stedim
Biotech
BIOSTAT STR®
Eppendorf CelliGen® BLU
Thermo Scientific HyPerforma™ SUB
Merck Mobius CellReady
Pall Life Sciences Nucleo®
GE Healthcare Xcellerex™ XDR
Wave-mixed Benchtop scale
(0.5–1.5 L)*
Applicon Appiflex 1.9 ∙105 cells/mL
hASC, hUC-MSC
Timmins et al. (2012); Jossen et al.
(2016)
Sartorius Stedim
Biotech
BIOSTAT® RM
Finesse SmartRocker
GE Healthcare WAVE
Pall Life Sciences XRS bioreactor
Hollow fiber Benchtop scale FiberCell
Systems
FiberCell 108–109 hMSCs Hambor (2012); Hanley et al. (2014)
(n/a)* Terumo BCT Quantum Cell
Expansion
Fixed bed Benchtop scale Eppendorf BioBLU® 5p 2.93 106 hMSC/mL Weber et al. (2010); Rowley et al.
(2012); Tsai and Ma (2016)(1.0–5.0 L)* Pall iCellis™
*Working volume
Fig. 2 Instrumented single-use
bioreactors suitable to expand
hMSCs and their working princi-
ples. (A) Stirred, (B) wave-mixed,
(C) hollow fiber bioreactor, and
(D) fixed bed bioreactor
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2016). However, due to their small size, reliable sampling is
still a challenge. Benchtop scale stirred bioreactors are pre-
ferred for first scale-up studies during the development of
hMSC production processes, whereas the pilot/production
scale stirred single-use bioreactors are regarded as qualified
production systems. They enable GMP production of hMSCs
in a class C or D room and render a class A cabinet or a class B
room unnecessary (Sensebé et al. 2013). For example,
Schirmaier et al. (2014) and Lawson et al. (2017) described
hMSC production processes in the BIOSTAT® STR 50L and
the Mobius® 50L bioreactor. Both research teams cultivated
hASCs and hBM-MSCs together with microcarriers and
reached maximum expansion factors of 53 (3.1 × 105
hASCs/mL) under serum-reduced conditions (5% FBS) and
43 ( 1 . 9 × 10 5 hBM-MSCs /mL) unde r common
serum-conditions (10% FBS). The generated cell densities
are sufficient to manufacture up to 177 clinical hMSC doses,
assuming that 106 hMSCs per kilogram body weight are ap-
plied. Rios and Gupta (2016) even reported maximum cell
densities of 2.0 × 106 hMSCs/mL at 50 L working volume.
As also seen in our own investigations, an optimized feeding
solution or/and feeding strategy can result in a process inten-
sification as indicated by two or threefold higher cell densities
(data are not shown).
It is worth mentioning that hMSC expansion processes
running between 6 and 10 days usually represent
batch-exchange approaches (Rios and Gupta 2016; Abraham
et al. 2017). After 3 to 5 days, microcarriers are allowed to
settle down before about 50% of the culture medium is re-
placed with fresh medium. This procedure is extremely labor
intensive, and the sedimentation of the microcarriers might
support the formation of large hMSC-microcarrier aggregates
which are unwanted (see also BMicrocarriers and their settle-
ment in hMSC manufacturing^ section). For this reason, allo-
geneic hMSC productions with periodical feeding and without
medium exchange or with a continuous exchange of medium
are underway (Rios and Gupta 2016; Abraham et al. 2017;
Lawson et al. 2017). These developments presuppose
microcarrier feeding as well as successful cell-to-bead and
bead-to-bead transfer. For example, Leber et al. (2017) and
Rafiq et al. (2017) have shown that freshly added
microcarriers can be colonized by the hMSCs. However, the
efficiency of the cell-to-bead and bead-to-bead transfer that is
impacted by the microcarrier and its settlement still needs
improvement (Takahashi et al. 2016).
Microcarriers and their settlement in hMSC
manufacturing
Microcarriers, which usually have a spherical shape, provide a
high surface area to volume ratio under fully controlled pro-
cess conditions in hMSC expansions realized in instrumented
bioreactors. Furthermore, the growth surface can be increased
within the bioreactor system to some extent, which improves
the product consistency and decreases the costs due to the full
use of very expensive culture media (see also BCulture medi-
um and supplements applied in hMSC expansions^ section)
applied in hMSC expansions. The microcarrier type plays a
key role in the cell expansion process where it is important
that the critical quality attributes (CQAs) do not change.
Numerous commercially available microcarrier types have al-
ready been tested in combination with hMSCs and stirred
bioreactors (Table 3). The microcarrier types differ greatly in
size (90–380 μm), core material (modified polystyrene, cellu-
lose, dextran, gelatine) as well as in surface coating (collagen,
fibronectin, diethylaminoethyl, triethylammonium). The core
material and the surface coating do not only affect the
microcarrier settlement and cell growth but also the impeller
speed which is required to hold the microcarriers in
suspension and to guarantee a sufficient mass transfer.
Moreover, grinding events as present in certain bioreactor
impeller bearings might be particularly problematic and may
require subsequent purification steps downstream of cell
production or, indeed, switching of bioreactor system. Rafiq
et al. (2016) and Leber et al. (2017) screened different
microcarrier types in small-scale bioreactors for hBM-MSCs
under predefined impeller speeds (Njs = impeller speed re-
quired to hold the microcarriers in suspension). Both found
significant differences in the cell attachment, cell growth, glu-
cose consumption as well as the production of metabolites
(e.g., lactate, ammonia) depending on the microcarrier type.
They found that the hBM-MSCs have the best growth perfor-
mance on collagen, Synthemax II, and ProNectin F
microcarriers. This comes as no surprise, since these
microcarriers are coated with collagen and fibronectin, respec-
tively. Both coatings are components of the extracellular ma-
trix (ECM), including the arginyl-glycyl-aspartic acid se-
quence which is well known for promoting cell attachment
and cell growth of fastidious cells (Szczypka et al. 2014).
Although, animal-free collagens are becoming more readily
available, many collagen coatings are still derived from ani-
mal sources which is critical from a regulatory point of view
(see also BRegulatory issues and challenges^ section).
Interestingly, investigations from different research groups
have demonstrated that different microcarrier surface sub-
strates can cause a change in the phenotype, which becomes
noticeable by a reduction in the expression level of different
surface markers (e.g., CD90, CD105, CD166) (Keung et al.
2010; Sart et al. 2013; Rios and Gupta 2016). Moreover, re-
cent studies have shown that the planar structure, including
the material stiffness, nanotopography, and local curvature,
can impact hMSC proliferation, maintenance of phenotype,
and differentiation (Yim and Sheetz 2012; Zhao et al. 2014).
Thus, many efforts are being made to develop new
GMP-grade biodegradable microcarriers in the next years.
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So far, the efficiency of microcarrier settlement covering
the cell attachment and spreading and the hMSC growth is
likewise dependent on the cell seeding process. In general,
the cell attachment follows a Poisson distribution, where a
cell-to-bead inoculation ratio of one, two, or three results in
theoretical probabilities of unoccupied microcarriers of 0.365,
0.135, and 0.05 (Frauenschuh et al. 2007; Panchalingam et al.
2015). Thus, it is important to inoculate with a high
cell-to-bead ratio in order to achieve a homogeneous cell dis-
tribution in which eachmicrocarrier is occupied by at least one
viable cell. Normally, a theoretical cell concentration of three
to five cells per microcarrier is used. After the attachment
phase, which normally takes between 4 to 20 h under static
or intermitted stirred conditions, every microcarrier should
have the same number of cells attached to its surface.
However, in practice, this is not the case. As the investigations
of our group (data not published) and Ferrari et al. (2012) have
shown, a suboptimal cell seeding results in the early formation
of large hMSC-microcarrier aggregates (up to 4–5 mm) which
impair cell growth and stem cell characteristics. As can also be
seen in Fig. 3, the aggregate size can be controlled by the
impeller speed and the resulting hydrodynamic forces. This
finding might be explained by the higher frequency of
particle-particle interactions that facilitate an aggregation, as
long as the hydrodynamic forces which can cause a cell de-
tachment are not too high. Big aggregates may be accompa-
nied by a decrease in the cell number which is explainable by
Culture medium and supplements applied in hMSC
expansions
Many of the conventional media used for the clinical produc-
tion of hMSCs are defined basal media such as DMEM
(Dulbecco’s modified Eagle medium) or α-MEM (Minimum
Essential Media). These have to be supplemented with expen-
sive additives such as (a) proteins which mediate adhesion to
tissue culture treated plastics, (b) lipids for cellular anabolic
purpose, and (c) growth factors and hormones to stimulate
cellular proliferation. Even though the disadvantages of serum
addition (high batch-to-batch variability, possible contamina-
tion with prions, viral and zoonotic agents, more difficult DSP
and product approval, elicitation of immunologic reactions;
Spees et al. 2004; Panchalingam et al. 2015) are known, the
majority of hMSC culture media additionally contain between
10 and 20% (vol/vol) fetal bovine serum (FBS).
Proven alternatives to FBS are humanized media which are
based on blood-derived materials such as human serum or
platelet derivate (Tekkatte et al. 2011). However, humanized
media are not applicable to routinely manufacture large
Table 3 Overview of microcarriers used for the expansion of hMSCs
Carrier Manufacturer Diameter (μm) Material Coating References
Xeno-free microcarriers
Cytodex 1 GE Healthcare 147–248 Dextran DEAE Takahashi et al. (2016); Rafiq et al. (2017)
Cytopore 1 GE Healthcare 200–280 Cellulose DEAE Takahashi et al. (2016)
Enh. Attach. Corning 125–212 PS CellBIND® Rafiq et al. (2016); Leber et al. (2017)
Glass SoloHill 125–212 PS Silica glass Rafiq et al. (2016); Leber et al. (2017)
Hillex® SoloHill 160–180 Dextran TRA Rafiq et al. (2016, 2017)
Hillex® CT SoloHill 90–212 PS TRA Rafiq et al. (2016, 2017)
Plastic SoloHill 125–212 PS None Rafiq et al. (2016, 2017); Nienow et al. (2016b)
Plastic Plus SoloHill 125–212 PS None Rafiq et al. (2016); Leber et al. (2017)
Star Plus SoloHill 125–212 PS None Meiring et al. (2016)
Synthemax II Corning 125–212 PS Sy II® Rafiq et al. (2016); Leber et al. (2017)
Mammalian protein-coated microcarriers
Collagen SoloHill 125–212 PS Collagen Nienow et al. (2016b); Leber et al. (2017); Lawson et al. (2017)
CultiSpherG Percell Biolytica 130–380 Gelatin None Rafiq et al. (2016)
Cytodex 3 Ge Healthcare 141–211 Dextran Collagen Sart and Agathos (2016)
FACT III SoloHill 125–212 PS Collagen Rafiq et al. (2016)
Recombinant protein-based microcarriers
ProNectin F® SoloHill 125–212 PS Fibronectin Jossen et al. (2016); Rafiq et al. (2016); Leber et al. (2017)
DEAE diethylaminoethyl, PS polystyrene, Sy synthemax, TEA triethylammonium
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the reduced viability in the cores of the aggregates. However,
i t is not yet fully understood to what extent the
hMSC-microcarrier aggregate formation has an influence on
the cell quality and which influence the medium composition
has on the hMSC characteristics.
numbers of hMSCs for allogeneic therapies due to high me-
dium amounts and resulting costs. Moreover, the supply of
high amounts of human serum is difficult to guarantee
(Shahdadfar et al. 2005). Instead of human serum, human
platelet lysate (hPL) was successfully applied by different
groups in hMSC productions (Hemeda et al. 2014; Burnouf
et al. 2016). Even though some studies have demonstrated the
same proliferation potential and marker expression as in se-
rum containing media, it is still controversially discussed
whether the cells retain their immunomodulatory properties
and their full differentiation capabilities (Gruber et al. 2004;
Lange et al. 2007; Abdelrazik et al. 2011). Although human
serum and hPL are considered to be safer than FBS, there is
still a risk of human pathogens and their components being
poorly characterized which may have an effect on the CQAs.
This explains why there exists a high level of interest in xeno
(XF) and serum-free (SF), chemically defined (CD) media for
the clinical production of hMSCs.
In addition to the different XD/SF and CD media devel-
oped by academic groups (Salzig et al. 2015; Tan et al. 2016),
various other formulations are on the market (e.g.,
MSCGM-CD from Lonza, Mesencult-XF from STEMCELL
Technologies, PRIME-XV SFM from Irvine Scientific,
StemPro MSC SFM XenoFree from Life Technologies,
stemgro hMSC from Corning, StemXVivo® serum-free from
R&D systems, SteMaxOne™ f rom Cel l Cul ture
Technologies, StemMACS™ XF from Miltenyi Biotec). The
choice of the right SF as well as CD medium or the
supplementation of an XF basal mediumwith the right growth
factors and hormones should not be underestimated (Tekkatte
et al. 2011), in particular when it is working in stirred biore-
actors with microcarriers. In this case, special attention has to
be given to the cell attachment efficiency (that can be lower
without serum; Salzig et al. 2015; Leber et al. 2017) and the
shear stress sensitivity (that is reduced without serum and
requires modified process parameters or/and the addition of
shear protective agents such as methylcellulose acetate). It is a
fact that the expansion factors obtained so far in stirred biore-
actors with XF/SF media are still significantly lower (up to 6
times) compared to those achieved in serum containingmedia.
For example, Heathman (2015) reported a maximum expan-
sion factor of up to 10 (hBM-MSCs) within 6 days with the
PRIME-XV SFmedium and a polystyrene-based microcarrier
(non-porous) specifically coated with fibronectin. Tan et al.
(2015) used Wharton’s Jelly-derived hMSCs in combination
with the Mesencult-XF medium and a microporous
microcarrier and reach an expansion factor of 6 within 6 days.
These results might indicate that the use of microporous or
even macroporous microcarriers is beneficial in combination
with the XF/SF medium due to the higher shear protection in
the porous carriers. But such microcarriers increase the com-
plexity of the DSP. For planar expansions of hMSCs, accept-
able CD media solutions are already commercially available.
Our group reached comparable cell numbers (50,000–60,000
cells/cm2) when growing hBM-MSCs and hASCs in planar
cultivation systems both with and without serum. The
Fig. 3 Effect of impeller speed on hMSC/MC-agglomerate formation.
Macroscopic (I) and microscopic (II) images of hMSC-microcarrier-
agglomerates at 25 rpm (a), 49 rpm (b), and 120 rpm (c) in single-use
spinner flasks. The white arrows indicate the hMSC-microcarrier-ag-
glomerates. The white scale bar corresponds to 1 mm
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cultivations were executed with two CD culture media,
MSCGM-CD from Lonza and UrSuppe-9 medium from the
Cardio Centro Lugano. The results allow us to conclude that
we need more suitable medium-microcarrier combinations for
XD/SF or CD media in stirred single-use bioreactor-based
expansions of hMSCs. Moreover, given these developments,
one might speculate that developing and obtaining regulatory
approval for serum-based products will become increasingly
difficult.
Further attention must be paid to the possible appearance of
extractables and leachables (chemical substances migrating
from the plastic contact layer into the culture medium with
cells) and to the adsorptions of medium components, all of
which may result in reduced cell growth or even cell death
(Mire-Sluis et al. 2016). Leachables are most dreaded for
single-use systems, because they occur under real process
conditions and, in the worst case, can be toxic for the patient.
Until now, only leachable studies for SF animal cell-based
productions of therapeutic proteins (in the majority monoclo-
nal antibody productions with Chinese Hamster Ovary (CHO)
cells) have been published (Steiger and Eibl 2013; Eibl et al.
2014; Jurkiewicz et al. 2014; Tappe et al. 2016). Blaschczock
et al. (2016) also investigated the growth of hMSCs with dif-
ferent bioreactor bag films, but these studies were conducted
with serum-containing medium. Film investigations with SF
growing hMSCs are missing. They have an influence on the
selection of the stirred single-use bioreactor type, because the
different manufacturers apply different plastic materials and
bag film layers. When growing hMSCs without serum, the
early identification of critical plastic material with respect to
extractables and leachables becomes more stringent. But ex-
tractable and leachable studies are more important for the DSP
equipment in hMSC expansions without serum, because DSP
unit operations are closer to the patient than USP unit opera-
tions. In addition, the expanded hMSCs represent the product
itself which bears a higher safety risk than those of therapeutic
protein productions with many purification steps.
Downstream processing of hMSCs
Cell detachment and separation
The DSP of clinical hMSC manufacturing has the largest
share of bottlenecks compared to USP because of the short
window of time available to transfer hMSCs from the culture
medium into the cryopreserved state (Abraham et al. 2017).
They are the reason why the production capacity is limited to
150–200 L per batch in allogeneic hMSC productions at pres-
ent. The first step after the bioreactor cultivation has been
completed is the detachment of the cells from the
microcarriers, which is mainly performed by proteolytic en-
zymes (e.g., trypsin). Here, the targets of the proteolytic en-
zyme are adhesion proteins on the cell surface. However, if
biodegradable microcarriers are used, a mixture of two en-
zymes is applied, where the second enzyme (e.g., collagenase)
targets the microcarrier structure. The development of such
GMP-grade microcarriers is the focus of latest developments,
because they significantly reduce the complexity of the sub-
sequent separation step. Yet, in both cases, the detachment of
the hMSCs from the microcarrier surface is mainly affected by
the surface coating (e.g., ECM components such as collagen
or fibronectin). Here, it is decisive to optimize the cell detach-
ment procedure with respect to the maximum time the cells
can be exposed to the enzyme as well as to the pH and
temperature for optimal enzymatic activity. Salzig et al.
(2015) tested different enzymes and ECM-components (col-
lagen, fibronectin, laminin, vitronectin) in combination with
FBS containing and SF media. They detected significant dif-
ferences in the cell detachment rate (up to 40%) and cell via-
bility (up to 20%) based on the surface coating and the en-
zyme used. Besides these aspects, it is also important to con-
sider enzyme quenching or proteolytic inhibitors, especially
when working with SF media after the cell detachment in
order to stop the enzymatic reaction. In general, the cell de-
tachment is mainly performed directly in the bioreactor sys-
tem because the system provides precise environmental con-
trol. At the end of the cultivation, the impeller is stopped and
the microcarriers are allowed to settle down on the reactor
bottom before the spent medium is removed via a dip tube.
At that point, the sedimentation velocity of the microcarriers
or cell-microcarrier aggregates is important. Microcarriers
with a density close to the medium density are beneficial in
order to hold them in suspension but not so for harvesting. In
the latest case, the Alternating Tangential Filtration (ATF)
technology from Repligen can be used prior to cell detach-
ment to concentrate and wash the hMSC-microcarrier suspen-
sion. XCell™ ATF modules represent effective devices to
filtrate large culture volumes, while a fouling of the filtration
membrane by the microcarriers is minimized (Schnitzler et al.
2016). However, it is important to define the optimum cycle
times and cycle conditions to guarantee high cell recovery.
During the cell detachment process, specific mechanical
loads are normally applied to facilitate cell detachment. For
example, Nienow et al. (2016b) used trypsin/EDTA solution
together with an increased impeller speed (5xNJS) to improve
the cell detachment from different coated and non-coated
microcarriers. They worked with maximum specific power
inputs of up to 2.23 W/kg and did not measure a reduction
in cell viability (> 95%) or the CQAs. However, it should be
kept in mind that the maximum power input and the resulting
enzymatic treatment duration are influenced by the bioreactor
type and its impellers.
After cell detachment, cells have to be separated from
microcarrier beads, a process which is normally accomplished
by size exclusion filtration based on size differences between
detached hMSCs (~ 15–20 μm) and microcarriers (> 90 μm).
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At small scale, bead separation is commonly carried out using
small sterile sieves such as cell strainers from Corning or
blood filters from Baxter Healthcare. Our group also success-
fully used a sterile sieve (reusable) to harvest hMSCs from
microcarriers contained in 50-L culture broth (Schirmaier
et al. 2014). Schnitzler et al. (2017) applied common flow
filtration device such as Steriflip® or Opticap®, which is based
on a woven mesh, and separated the cells from the
microcarrier beads. The single-use Harvestainer™
BioProcess Container (BPC) from Thermo Scientific is de-
signed for small- and large-scale applications. When up to
12-L microcarrier beads have to be separated, the 3- or 12-L
Harvestainer solution, consisting of a pillow-like bag and a
tray, is ideal (Fig. 4a). The large-scale Harvestainer, a sche-
matic drawing of which is shown in Fig. 4b, consists of a
bag-in-bag design. The microcarriers are retained by the one
or two inner Microbarrier Labtainer 25-L BPCs, while the
hMSCs which are free of microcarrier beads and fragments
can flow into the outer 200-L bag for further processing.
Independent of the device and scale used, the target is cell
recoveries and viabilities exceeding 90%. Particular emphasis
has to be given to particulates (see also BParticulates^ section).
This is especially true when microcarrier debris may be gen-
erated by pumping out the suspension. If the resulting
microcarrier debris is smaller than the filter pore size, it may
contaminate the final ATMP.
Cell washing and concentration
Cell washing following cell detachment is required to remove
any unwanted components such as FBS residues, enzyme or
microcarrier debris from the cell suspension. Typically, wash-
ing is performed together with the cell concentration step
needed due to the required high cell numbers (106–107 cells/
mL) in the final formulation. Cell washing and concentration
are either performed by tangential flow filtration (TFF) or by
centrifugation.
TFF technology is well established in the purification of
mammalian cell-based therapeutic proteins. Here, the proteins
on the filtrate side are the desired product. However, the TFF
technology can be adapted for clinical hMSC manufacturing
by keeping the shear rate and pressure low enough. This
means that the cell viability and the cell phenotype are not
allowed to be affected during concentration and washing.
Pattasseril et al. (2013) have reported a 60- to 100-fold con-
centration of hMSCs with TFF technology while maintaining
cell viability and recovery at a high level. Reusable and
single-use TFF systems are provided by different vendors
such as EMD Millipore, Pall, Sartorius Stedim, GE
Healthcare etc. However, the optimal flow rate and pressure
need to be screened early in the process development in order
to maximize the cell recovery.
Classical centrifugation technology is suboptimal for clin-
ical processing of hMSCs, since the centrifugal forces com-
pact the cells against each other and against a solid surface;
cells need to be mechanically segregated subsequently, and
this is likely detrimental to the cells and reduces cell recovery
as well as washing efficacy. Thus, continuous flow centrifu-
gation technology should be applied. The kSep® system from
Sartorius Stedim Biotech represents a very promising device
because it contains single-use tubings which are replaced after
each process. hMSCs are concentrated in a fluidized bed
Fig. 4 Single-use Harvestainer
solution for small scale (a) and
large scale (b) (with kind
permission of Thermo Scientific)
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under a continuous flow, while the clear supernatant is re-
moved continuously. With the kSep 400 (volumetric flow rate
of 114 L/h) and the kSep 6000S (volumetric flow rate of
720 L/h), the processing of high volumes within a short time
becomes possible (Sartorius Stedim Biotech 2017).
Independent from the technology and devices used for cell
washing and concentration during the hMSC manufacture, it
has to be shown once again that the concentrated hMSC cul-
ture broth contains no impurities. This also applies to the
subsequent medium exchange executed with diafiltration de-
vices and representing the last step of the DSP in hMSC man-
ufacture (Abraham et al. 2017).
Regulatory issues and challenges
Regulatory paths and agencies in the EU, USA, and Asia
In the EU, products containing living cells (and/or products of
gene therapy or tissue engineering efforts) are regulated by the
ATMP regulatory path (for a review, see van den Bos (2012)).
Apart from common, drug-related GMP requirements, it stip-
ulates a central procedure towards the European Market
Authorization issued by the European Medicine Agency
(EMA 2017). Of note, individual EUmember countries offers
alternative regulatory paths for products which are early in the
development phase or which target exceptionally rare diseases
and/or are not targeted for routine production: the so-called
hospital exemption (see as follows for a review). In the USA,
such products require a license from the Centre for Biologics
Evaluation and Research /Food and Drug Administration, and
in Asia, for example in India, must be approval by the Cellular
Biology Based Therapeutic Drug Evaluation Committee ad-
vising the central regulatory agency—Central Drugs Standard
Control Organization (reviewed in van den Bos et al. (2017)).
Unsurprisingly, it is advisable to get in touch with the author-
ities as early as possible and, for example, the European
Medicine Agency offers consultations for scientific advice
as well as the option of having one’s preclinical work certified
(Agency 2007), something which investors and/or strategic
partners might appreciate. At the national level, individual
member states offer various ways of providing advice, for
example, the German national authority, the Paul Ehrlich
Institute, offers input through its innovation office (Advice
2011).
Process specifics
Many ATMP products cannot be sterilized terminally which
means that the entire production process is required to be
aseptic. This typically requires processes to be set up in ap-
propriate clean room cascades and/or in closed systems; it also
requires risk-based assessments of high-risk process steps and
their control by in-process controls; the latter rationale and
execution tend to be subject for in-depth discussions with
authorities.
Product characterization and specification
Perhaps the most pertinent issue in regard to quality and
regulatory procedures is that of characterizing and specify-
ing the product. Active Pharmaceutical Ingredients (APIs)
comprising small molecules can be characterized on a
per-atom basis, larger molecules such as antibodies, while
clearly more complex, can still be characterized substan-
tially. Cellular products, however, pose a significant prob-
lem in this regard.
First, therapeutic effects are sometimes observed; yet,
mechanisms of action are not fully understood, complicating
the choice of specifications. Second, the sheer complexity of
living mammalian cells makes characterization extraordinari-
ly difficult. While size/mass might only be a surrogate of
complexity, it might help to illuminate the challenge: the mo-
lecular weight of a mammalian cell has been calculated to be
2 × 1012 times that of a small molecule (van den Bos et al.
2013). Thus, one might consider the comparable complexity
of a mammalian cell to be very high indeed and, in turn, our
ability to characterize it to be rather limited. Consequently, the
process of manufacture assumes a prominent role in product
characterization. Thus, changing the process from, for exam-
ple, static culture to 3D culture, requires the innovator to make
a case for product similarity while describing a highly com-
plex API, something which is likely to be a point of discussion
with authorities.
Mesenchymal stem cells (MSCs) have been character-
ized by their adherence to serum coated plastic in static cell
culture by morphology (Friedenstein et al. 1970) and by
expression of certain surface markers often detected by
flow cytometry (Dominici et al. 2006; Bourin et al.
2013). While a combination of such markers/features has
been useful to distinguish MSCs from other cells found in
source tissues such as bone marrow or fat, the functional
diagnostic value of such features and markers is debatable
as it is difficult to associate them with particular MSC
functions. This, and the absence of a single specific marker
such as CD34 for hematopoietic stem cells, poses a prob-
lem in product characterization/specification. Therefore, it
appears prudent to choose quantifiable markers which are
also known to be directly involved in MSC functionality;
secreted bioactive factors such as vascular endothelial
growth factor, a factor involved in neovascularization, or
enzymatic activities such as that of indolamine oxydase, an
enzyme involved in the immune modulation through catab-
olism of tryptophan (reviewed in Mellor (2005)) have
emerged as prime candidates (reviewed in van den Bos
et al. (2013)). Depending on the intended product features,
other markers may be chosen following the same rationale.
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Particulates
Sometimes, cellular products are injected intravenously and
hence might be considered parenteral drugs. These are re-
quired to be controlled in regard to particles, both visible
and subvisible in size (see USP 787, 788, EU pharmacopeia
2.9.19). Apart from particulate matter potentially present in
single-use equipment, microcarriers may, as discussed previ-
ously, contribute to the particle load of a cellular product. For
any process development, it seems advisable to control for
microcarrier fracturing and any potentially resulting particles.
Indeed, it might be advisable to integrate this consideration
into the original process development and to make low
microcarrier-derived particulate levels part of the selection
criteria for microcarriers.
Product dosing
MSCs are sometimes dosed at 1–2 × 106 cells kg body weight,
and this range seems to be derived empirically. A rationale for
a dose might be based on desired quantifiable effects; for
example, (a) which level of a bioactive factor is required in a
tissue to cause a desirable effect, (b) at which level do hMSCs
produce such a factor, (c) how does being in a tissue affect
hMSC bioactive factor secretion levels, and (d) how many
hMSCs are actually present in a tissue post application. If all
of these are known, one should be able to calculate the re-
quired dose. Some of the questions, for example, (b) may be
answered more easily than others, and a full set of data may
not always be available. Consequently, dosing of MSCs may
be based on observed therapeutic effects rather than a fully
developed rationale and, as such, may be a point of discussion
with authorities.
Product availability and storage
A campaign to manufacture larger quantities of MSCs might
take 3 months including release testing. Since MSCs are often
used in allogenic contexts and cryogenic storage is known to
be able to preserve viability even for such fragile cells as
CD34+ hematopoietic stem cells for decades (Broxmeyer
et al. 2003), MSC-based products can be manufactured in
advance and be retrieved from storage when needed.
Assuming successful stability studies, manufacturers may
thus produce in campaigns followed by potentially extended
cryostorage until use. Unfortunately, sometimes, product sta-
bility appears to be substantially less than expected and this
may raise quality/regulatory/economic questions. It is likely
that cells which have been frozen properly, i.e., using appro-
priate freezing rates and suitably applied cryoprotectant, will
be stable for long periods of time. If, despite this, one observes
stability issues, one might consider insufficient/uneven con-
centrations of cryoprotectant or unintended events of elevated
temperatures; these might be unlikely if cells are stored in the
liquid nitrogen phase. However, it has been demonstrated that
cross contamination is possible between samples stored in the
liquid nitrogen phase (Bielanski et al. n.d.). Thus, for reasons
of avoiding cross contamination, products are frequently
stored in the vapor phase. While temperatures in the vapor
phase are typically sufficiently low to warrant proper storage,
the vapor phase is more susceptible to disturbance by, for
example, adding or removing racks, thereby increasing the
risk of accidental warming events potentially leading to a
compromised product.
Conclusions and outlook
Cell therapeutics for regenerative medicine are currently in the
spotlight for researchers and manufacturers. A few
hMSC-based products have already been given marketing au-
thorization and are routinely used in clinics worldwide.
However, in order to make the therapies available to a broad
group of patients, interest in allogeneic therapies is particularly
high. Thus, previously used planar process platforms are in-
creasingly being replaced by instrumented single-use bioreac-
tors which operate with microcarriers. Although different
groups have already worked successfully with wave-mixed
and fixed bed bioreactors, the stirred bioreactors have deliv-
ered the most promising results so far. It is believed that com-
mercially obtainable stirred single-use bioreactors of up to
200 L culture volume are sufficient to produce hMSC-based
cell therapeutic products for allogeneic therapies. However,
process optimization potential still exists for XF/SF and CD
culture media, which should prove cell densities of up to 1 ×
106 cells/mL in the future. Furthermore, culture media should
be adapted to degradable GMP-grade microcarriers in order to
facilitate cell growth and harvesting. The possibility of process
intensification by periodical feeding and continuous medium
removal has to be studied for new medium formulations. This
also includes optimization of the cell-to-bead and bead-to-bead
transfer and the control of the cell-microcarrier-aggregate for-
mation. The increasing implementation of single-use devices
for the USP and DSP in SF hMSC production processes may
contribute to higher process and patient safety, and
presupposed extractables and leachables at critical levels can
be also excluded. But this requires risk analyses and extract-
able and leachable studies for hMSC production processes for
which no recommendations yet exist. Even though a clear
regulatory path for the approval of hMSC-based products does
exist, certain challenges remain. One such challenge might be
the problem of particulates because hMSCs-based products
cannot be terminally filter sterilized. Also, from a regulatory
point of view, one might speculate that developing and
obtaining regulatory approval for serum-based products will
become increasingly difficult in the future.
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